Stock Under $10 with 50-100% upside potential - 14 Days FREE!

Hospira Receives FDA Clearance For Symbiq⿢ 3.13 Infusion Pump

Stock quotes in this article: HSP 

LAKE FOREST, Ill., March 8, 2012 /PRNewswire/ --  Hospira, Inc. (NYSE: HSP), the world's leading provider of injectable drugs and infusion technologies, announced today that the company has received regulatory clearance from the U.S. Food and Drug Administration (FDA) for the Symbiq™ 3.13 infusion device, the enhanced version of the company's advanced infusion system platform. The clearance is one of the first to be granted through the new draft FDA regulatory guidance for 510(k) infusion pump submissions. Hospira is planning to start working with current customers to upgrade to the enhanced Symbiq device in the first quarter and expects to begin shipments to previously contracted customers in the second quarter. 

"With the new Symbiq system, Hospira will provide clinicians and patients with one of the most technologically advanced and highest quality infusion pumps available," said Sumant Ramachandra, M.D., Ph.D., senior vice president, Research & Development and Medical & Regulatory Affairs, and chief scientific officer, Hospira. "We took a device that was designed to transform how hospitals deliver medications safely and reflect real-world clinician feedback, and then put the system through a rigorous development and regulatory process to increase its reliability."

New Symbiq infusion pump innovations reflect how the device is used to administer medication at the patient's bedside. Symbiq platform enhancements include:

  • more robust connectivity and wireless communication to enhance I.V. Clinical Integration,
  • improved software reliability, enabling more consistent performance across a range of clinical applications, and
  • updated software design that better supports optimal performance.

The Symbiq infusion system is a technologically advanced infusion device with clinician-friendly features designed to help improve workflow and decrease medication errors. For example, the Symbiq LCD touch screen -- the largest infusion pump screen available -- includes intuitive layouts and touch-activated buttons. This unique touch-screen technology also enables hospitals to add future applications or "apps."

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 15,323.38 16.21 0.11%
NASDAQ 3,463.23 -0.07 0.00%
S&P 500 1,653.26 -2.09 -0.13%
US 10 Yr 2.028% +0.002

Brokerage Partners

Advertising Partners
Special Features

Free Newsletters from TheStreet

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy. Manage Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs